Utah Medical Products, Inc. (UTMD) Stock

Utah Medical Products, Inc. (UTMD) is a Healthcare stock trading at $71.40 (as of 2026-08-20), with a market capitalization of $227.34M and a trailing P/E of 21.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices used in healthcare settings, including labor and delivery accessories and systems, neonatal respiratory hoods, and blood pressure monitoring equipment. The company also supplies products such as catheters, dialysis and urinary drainage sets, electrosurgical generators and electrodes, and related surgical instruments for clinical use.

Understand Utah Medical Products, Inc.: how it makes money

Utah Medical Products, Inc. (UTMD) develops, manufactures, and distributes medical devices and accessories used in areas like labor and delivery, infant respiratory care, blood pressure monitoring, and dialysis and feeding, and it makes money from net sales of these products to healthcare customers.

The profit model is tightly linked to turning product into sales while controlling working capital, since investors can monitor Days in Trade Receivables and Average Inventory Turns, and the company reports relatively strong gross margin and operating margin.

Revenue by segment (latest quarter)
Net Sales$0.0B

Business quality (Mixed): High reported margins for the latest quarter, but revenue is very small on the provided scale, so working capital conversion and execution across its specialized medical device portfolio are key watch points.

Valuation: At 19× earnings, UTMD trades 40% below the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

  • Reported gross margin is 60.6% (latest quarter): This suggests the product mix and manufacturing and distribution economics support strong profitability per dollar of sales.
  • Reported operating margin is 29.4% (latest quarter): Operating costs are not overwhelming gross profit in the period shown.

Bear case

  • Revenue is reported as 0.0B for the latest quarter on the provided scale: If sales remain very small, results may be more sensitive to customer demand shifts and quarter-to-quarter variability.
  • Working capital conversion may be a key issue, with Days in Trade Receivables at 37.5 and Average Inventory Turns at 1.7: Slower cash collection or slower inventory movement can pressure near-term results even when margins look strong.
Valuation — source: SEC EDGAR (first-party)
Price$71.40
Market Cap$227.34M
P/E Ratio21.6
EV / EBITDA11.8
Price / Book1.86
Price / Sales6.35
FCF Yield9.3%
DCF Value (model)$76.71
DCF Upside vs Price7.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$38.52M
Net Margin29.3%
Revenue Growth (YoY)-14.3%
EPS Growth (YoY)-10.6%
FCF Growth (YoY)-40.5%
Financial Health — source: SEC EDGAR
Altman Z-Score44.70 (safe)
Piotroski F-Score5/9 (moderate)
Valuation vs Sector & Industry
Stock P/E21.6
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
vs Sector0.0%
vs Industry-34.3%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBRANDES INVESTMENT PARTNERS, LP ($27.85M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOKevin L. Cornwell
Employees155
CountryUS
IPO Date1999-03-08

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Orchestra BioMed Holdings, Inc. (OBIO)
  • AVITA Medical, Inc. (RCEL)
  • OraSure Technologies, Inc. (OSUR)
  • InfuSystem Holdings, Inc. (INFU)
  • Neuronetics, Inc. (STIM)
  • Pro-Dex, Inc. (PDEX)
  • Lucid Diagnostics Inc. (LUCD)
  • IceCure Medical Ltd (ICCM)
UTMD earnings history · UTMD institutional & insider holders · UTMD KPIs & operating metrics · UTMD financials · UTMD investor presentations & press releases · UTMD SEC filings · UTMD peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.